Tricyclic benzazepine vasopressin antagonists

Details Tricyclic benzazepine vasopressin antagonists Tricyclic benzazepine vasopressin antagonists

1994-06-13

1996-04-30

Datlow, Philip I.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

540587, 540547, 540557, 540578, 540586, 546110, C07D22320, A61K 3155

Patent

active

055125638

ABSTRACT:
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

REFERENCES:
Yamamura, Y. et al, "OPC-21268, An Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist", Science, 252:572-574 (1991).
Yamamura, Y. et al., "Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide V2 antagonist", Br. J. Pharmacol., 105:787-791 (1992).
Drug Evaluations, 6th Edition (1986), Amer. Medical Assn, pp. 160-162.
Cecil Textbook of Medicine, 19th ed. (1992), Wyngaarden, M.D. editor, pp. 2075-2079.

Affiliated with

Also associated with

Rating

Tricyclic benzazepine vasopressin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic benzazepine vasopressin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic benzazepine vasopressin antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-628851